Monitoring Report: Respiratory Viruses - October 2024 Data

Samuel Gratzl, PhD

Brianna M Goodwin Cartwright, MS

Patricia J Rodriguez, PhD, MPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through November 03, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and November 03, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 744,168 hospitalizations of 688,099 unique patients who tested positive for a respiratory virus between October 01, 2019 and November 03, 2024.

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout October 2024; there was a 18.7 percentage point reduction in the rate of hospitalizations from the last week of September to the last week of October. However, influenza-, HMPV-, and RSV-associated hospitalizations all increased noticeably. COVID and rhinovirus-associated hospitalizations saw notable declines. In the last week of October 2024, respiratory virus-associated hospitalizations accounted for 1.9% of all hospitalizations. Overall, test positivity rates also decreased, with an overall drop of 10.6%. However, RSV test positivity increased by 189.6% to 3.3%. Influenza, HMPV, and parainfluenza virus also had increases in the rate of positive tests.

Respiratory virus-associated hospitalizations increased for infants and children (+21.6%), specifically, RSV-associated hospitalizations saw an increase of 233.3% and accounted for 2.4% of all hospitalizations in this population. Within this population, RSV test positivity also increased (+147.1%).

Discussion: The data indicates a continued decline in respiratory virus-associated hospitalizations across the overall population. However, the continued increases in parainfluenza and RSV hospitalizations, highlight the need for close surveillance. The

decrease in test positivity rates for COVID-19 and rhinovirus is encouraging, but the rising trend in influenza, HMPV, parainfluenza, and RSV positivity warrants attention as it may precede a seasonal peak of these viruses.

Trends in surveillance

Overall population



	Overall	COVID	influenza	HMPV	Parainfluenza virus	RSV	rhinovirus
September 30, 2024	2.3%	1.4%	0.1%	0.0%	0.1%	0.1%	0.9%
October 28, 2024	1.9%	0.9%	0.1%	0.0%	0.1%	0.2%	0.8%
Change (percentage)	-18.7%	-39.3%	+100.0%	+123.4%	+16.1%	+191.5%	-14.4%
Difference (percentage points)	-0.4%	-0.6%	+0.1%	+0.0%	+0.0%	+0.1%	-0.1%



	Overall	COVID	influenza	HMPV	Parainfluenza virus	RSV	rhinovirus
September 30, 2024	4.9%	8.3%	1.5%	0.3%	2.1%	1.1%	22.0%
October 28, 2024	4.4%	5.3%	2.5%	0.7%	3.4%	3.3%	20.4%
Change (percentage)	-10.6%	-36.2%	+62.6%	+115.7%	+56.1%	+189.6%	-7.1%
Difference (percentage points)	-0.5%	-3.0%	+0.9%	+0.4%	+1.2%	+2.2%	-1.5%

In the final week of October, respiratory virus-associated hospitalizations accounted for 1.9% of all hospitalizations, down from 2.3% in late September. The rate of hospitalizations associated with respiratory viruses decreased by 18.7% from

September 30, 2024, to October 28, 2024. The decline in COVID-associated hospitalizations (-39.3%) was the most substantial decrease. RSV-, Influenza- and HMPV-associated hospitalizations increased significantly (+191.5%, +100.0% and +123.4%, respectively); however, the percentage of overall hospitalizations associated with either HMPV or influenza remained low. Parainfluenza hospitalizations showed a moderate increase (+16.1%), while rhinovirus-associated hospitalizations decreased slightly (-14.4%).

Test positivity for respiratory viruses declined by 10.6%, with COVID test positivity experiencing the greatest drop (-36.2%). However, HMPV and RSV test positivity experienced substantial increases of +115.7% and +189.6%, respectively. Influenza test positivity also rose significantly (+62.6%), while rhinovirus test positivity decreased marginally to 20.4% (-7.1%), remaining the virus with the highest test positivity.

Infants and children (age 0-4)



	Overall	COVID	influenza	HMPV	Parainfluenza virus	RSV	rhinovirus
September 30, 2024	4.2%	1.4%	n/a	n/a	0.2%	0.7%	3.1%
October 28, 2024	5.1%	1.2%	0.1%	0.0%	0.2%	2.4%	3.2%
Change (percentage)	+21.6%	-18.4%			-24.3%	+233.3%	+1.9%
Difference (percentage points)	+0.9%	-0.3%			-0.1%	+1.7%	+0.1%



	Overall	COVID	influenza	HMPV	Parainfluenza virus	RSV	rhinovirus
September 30, 2024	8.3%	7.2%	2.3%	0.7%	7.5%	5.9%	52.2%
October 28, 2024	9.6%	5.8%	2.8%	1.4%	9.2%	14.5%	46.2%
Change (percentage)	+15.5%	-19.3%	+21.7%	+91.6%	+22.4%	+147.1%	-11.5%
Difference (percentage points)	+1.3%	-1.4%	+0.5%	+0.7%	+1.7%	+8.7%	-6.0%

In the population aged 0–4 years, respiratory virus-associated hospitalizations increased by 21.6% from September 30, 2024, to October 28, 2024. COVID-associated hospitalizations declined by 18.%, while RSV-associated hospitalizations surged dramatically by +233.3%. RSV-associated hospitalizations now account for 2.4% of all hospitalizations within this population. Parainfluenza-associated hospitalizations decreased slightly by 24.3%. In late October, 5.1% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus remaining a significant contributor at 3.2%.

The overall test positivity rate for respiratory viruses increased by 15.5%, driven by notable rises in HMPV (+91.6%), RSV (+147.1%) and parainfluenza (+22.4%) positivity rates. COVID test positivity decreased by 19.3%, and rhinovirus test positivity, while still high, declined to 46.2% (-11.5%).

Older adults (age 65 and over)



	Overall	COVID	influenza	HMPV	Parainfluenza virus	RSV	rhinovirus
September 30, 2024	2.7%	2.0%	0.1%	0.0%	0.1%	0.0%	0.6%
October 28, 2024	2.0%	1.2%	0.1%	0.0%	0.1%	0.1%	0.5%
Change (percentage)	-26.8%	-40.9%	+91.5%	+145.8%	+67.3%	+137.0%	-17.6%
Difference (percentage points)	-0.7%	-0.8%	+0.1%	+0.0%	+0.0%	+0.1%	-0.1%



	Overall	COVID	influenza	HMPV	Parainfluenza virus	RSV	rhinovirus
September 30, 2024	4.7%	11.2%	0.8%	0.1%	0.6%	0.2%	9.2%
October 28, 2024	3.3%	6.8%	1.0%	0.4%	1.5%	0.7%	8.6%
Change (percentage)	-30.7%	-39.2%	+32.5%	+249.1%	+144.8%	+208.8%	-6.7%
Difference (percentage points)	-1.4%	-4.4%	+0.3%	+0.3%	+0.9%	+0.5%	-0.6%

Among older adults (age 65 and over), hospitalizations associated with respiratory viruses decreased by 26.8% from September 30, 2024, to October 28, 2024. COVID-associated hospitalizations declined significantly (-40.9%), while influenza-associated hospitalizations increased by 91.5%. Hospitalizations related to RSV rose substantially

(+137.0%), while rhinovirus-associated hospitalizations decreased slightly (-17.6%). By late October, respiratory virus-associated hospitalizations accounted for 2.0% of all hospitalizations in this age group, with COVID and rhinovirus contributing 1.2% and 0.5%, respectively.

The overall test positivity rate for respiratory viruses declined by 30.7%, driven by a sharp drop in COVID test positivity (-39.2%). However, test positivity rates for HMPV (+249.1%), RSV (+208.8%) and parainfluenza (+144.8%) surged. Rhinovirus test positivity remained notable at 8.6%, though it decreased slightly (-6.7%). Influenza test positivity also rose moderately, reflecting a 32.5% increase.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and November 03, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on November 19, 2024 and included de-identified patient care data primarily located across ten states: Virginia, New York, Florida, California, Illinois, Ohio, Washington, North Carolina, Louisiana, and Arizona.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 744,168 hospitalizations of 688,099 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	93,031 (100.00%)	174,551 (100.00%)	179,184 (100.00%)	123,970 (100.00%)	112,690 (100.00%)	4,673 (100.00%)	688,099 (100.00%)
Age Group							
< 6 months	1,652 (1.78%)	1,262 (0.72%)	2,389 (1.33%)	2,998 (2.42%)	2,336 (2.07%)	110 (2.35%)	10,747 (1.56%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
6 - <12 months	747 (0.80%)	487 (0.28%)	1,067 (0.60%)	1,400 (1.13%)	1,171 (1.04%)	58 (1.24%)	4,930 (0.72%)
1 - <2 years	927 (1.00%)	847 (0.49%)	1,646 (0.92%)	1,993 (1.61%)	1,645 (1.46%)	111 (2.38%)	7,169 (1.04%)
2 - 4 years	1,200 (1.29%)	947 (0.54%)	2,355 (1.31%)	3,064 (2.47%)	2,159 (1.92%)	173 (3.70%)	9,898 (1.44%)
5 - 17 years	1,341 (1.44%)	1,732 (0.99%)	3,008 (1.68%)	3,449 (2.78%)	2,974 (2.64%)	260 (5.56%)	12,764 (1.85%)
18 - 49 years	19,456 (20.91%)	39,483 (22.62%)	37,678 (21.03%)	17,221 (13.89%)	15,116 (13.41%)	658 (14.08%)	129,612 (18.84%)
50 - 64 years	22,446 (24.13%)	44,086 (25.26%)	36,732 (20.50%)	19,520 (15.75%)	18,421 (16.35%)	722 (15.45%)	141,927 (20.63%)
65 - 74 years	18,320 (19.69%)	36,512 (20.92%)	36,150 (20.17%)	24,382 (19.67%)	22,678 (20.12%)	848 (18.15%)	138,890 (20.18%)
75 - 84 years	16,458 (17.69%)	31,214 (17.88%)	35,271 (19.68%)	28,902 (23.31%)	27,191 (24.13%)	1,024 (21.91%)	140,060 (20.35%)
85+ years	10,484 (11.27%)	17,981 (10.30%)	22,888 (12.77%)	21,041 (16.97%)	18,999 (16.86%)	709 (15.17%)	92,102 (13.38%)
Sex							
Female	46,363 (49.84%)	84,695 (48.52%)	91,663 (51.16%)	64,982 (52.42%)	58,864 (52.24%)	2,368 (50.67%)	348,935 (50.71%)
Male	45,610 (49.03%)	88,184 (50.52%)	85,832 (47.90%)	57,999 (46.78%)	52,675 (46.74%)	2,237 (47.87%)	332,537 (48.33%)
Other	0	3 (0.00%)	2 (0.00%)	3 (0.00%)	0	0	8 (0.00%)
Unknown	1,058 (1.14%)	1,669 (0.96%)	1,687 (0.94%)	986 (0.80%)	1,151 (1.02%)	68 (1.46%)	6,619 (0.96%)
Race							
White	50,893 (54.71%)	111,499 (63.88%)	121,209 (67.64%)	83,772 (67.57%)	74,513 (66.12%)	3,052 (65.31%)	444,938 (64.66%)
Black or African American	14,810 (15.92%)	22,172 (12.70%)	21,809 (12.17%)	14,007 (11.30%)	14,549 (12.91%)	627 (13.42%)	87,974 (12.79%)
Asian	2,716 (2.92%)	4,034 (2.31%)	3,850 (2.15%)	3,719 (3.00%)	2,890 (2.56%)	117 (2.50%)	17,326 (2.52%)
Native Hawaiian or Other Pacific Islander	357 (0.38%)	559 (0.32%)	521 (0.29%)	368 (0.30%)	340 (0.30%)	7 (0.15%)	2,152 (0.31%)
American Indian or Alaska Native	600 (0.64%)	1,051 (0.60%)	1,121 (0.63%)	823 (0.66%)	666 (0.59%)	31 (0.66%)	4,292 (0.62%)
Other Race	8,379 (9.01%)	12,431 (7.12%)	10,296 (5.75%)	8,380 (6.76%)	7,300 (6.48%)	381 (8.15%)	47,167 (6.85%)
Unknown	15,276 (16.42%)	22,805 (13.06%)	20,378 (11.37%)	12,901 (10.41%)	12,432 (11.03%)	458 (9.80%)	84,250 (12.24%)
Ethnicity							
Hispanic or Latino	12,967 (13.94%)	20,013 (11.47%)	16,499 (9.21%)	12,926 (10.43%)	12,564 (11.15%)	609 (13.03%)	75,578 (10.98%)
Not Hispanic or Latino	63,792 (68.57%)	128,893 (73.84%)	141,289 (78.85%)	97,799 (78.89%)	90,015 (79.88%)	3,760 (80.46%)	525,548 (76.38%)
Unknown	16,272 (17.49%)	25,645 (14.69%)	21,396 (11.94%)	13,245 (10.68%)	10,111 (8.97%)	304 (6.51%)	86,973 (12.64%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Virus							
COVID	60,520 (65.05%)	164,258 (94.10%)	156,410 (87.29%)	75,599 (60.98%)	60,847 (54.00%)	2,546 (54.48%)	520,180 (75.60%)
HMPV	2,616 (2.81%)	80 (0.05%)	2,203 (1.23%)	3,920 (3.16%)	3,352 (2.97%)	42 (0.90%)	12,213 (1.77%)
RSV	5,874 (6.31%)	1,969 (1.13%)	4,251 (2.37%)	7,673 (6.19%)	9,621 (8.54%)	189 (4.04%)	29,577 (4.30%)
influenza	14,592 (15.69%)	379 (0.22%)	4,703 (2.62%)	17,178 (13.86%)	20,538 (18.23%)	213 (4.56%)	57,603 (8.37%)
parainfluenza	1,391 (1.50%)	1,416 (0.81%)	2,349 (1.31%)	4,312 (3.48%)	3,719 (3.30%)	179 (3.83%)	13,366 (1.94%)
rhinovirus	8,038 (8.64%)	6,449 (3.69%)	9,268 (5.17%)	15,288 (12.33%)	14,613 (12.97%)	1,504 (32.18%)	55,160 (8.02%)
Comorbidity							
Asthma	8,635 (9.28%)	13,849 (7.93%)	17,037 (9.51%)	14,632 (11.80%)	14,656 (13.01%)	700 (14.98%)	69,509 (10.10%)
Chronic Lung Disease	6,098 (6.55%)	10,674 (6.12%)	11,620 (6.48%)	9,122 (7.36%)	9,041 (8.02%)	412 (8.82%)	46,967 (6.83%)
Chronic Obstructive Pulmonary Disease	11,843 (12.73%)	18,826 (10.79%)	25,821 (14.41%)	21,431 (17.29%)	21,305 (18.91%)	947 (20.27%)	100,173 (14.56%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



Test positivity rate over time

We included 51,195,005 lab results with known results of which 4,860,362 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2019



COVID-19

Our COVID study population consists of 539,786 hospitalizations of 520,180 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	60,520 (100.00%)	164,258 (100.00%)	156,410 (100.00%)	75,599 (100.00%)	60,847 (100.00%)	2,546 (100.00%)	520,180 (100.00%)
Age Group							
< 6 months	108 (0.18%)	310 (0.19%)	741 (0.47%)	411 (0.54%)	348 (0.57%)	24 (0.94%)	1,942 (0.37%)
6 - <12 months	37 (0.06%)	52 (0.03%)	254 (0.16%)	202 (0.27%)	214 (0.35%)	14 (0.55%)	773 (0.15%)
1 - <2 years	55 (0.09%)	98 (0.06%)	257 (0.16%)	189 (0.25%)	250 (0.41%)	40 (1.57%)	889 (0.17%)
2 - 4 years	102 (0.17%)	106 (0.06%)	391 (0.25%)	260 (0.34%)	303 (0.50%)	44 (1.73%)	1,206 (0.23%)
5 - 17 years	341 (0.56%)	887 (0.54%)	1,336 (0.85%)	562 (0.74%)	621 (1.02%)	108 (4.24%)	3,855 (0.74%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
18 - 49 years	14,257 (23.56%)	37,664 (22.93%)	34,349 (21.96%)	9,855 (13.04%)	6,602 (10.85%)	233 (9.15%)	102,960 (19.79%)
50 - 64 years	15,687 (25.92%)	42,504 (25.88%)	33,393 (21.35%)	11,480 (15.19%)	8,800 (14.46%)	335 (13.16%)	112,199 (21.57%)
65 - 74 years	12,273 (20.28%)	35,184 (21.42%)	32,713 (20.91%)	15,959 (21.11%)	12,957 (21.29%)	495 (19.44%)	109,581 (21.07%)
75 - 84 years	10,916 (18.04%)	30,125 (18.34%)	32,124 (20.54%)	20,752 (27.45%)	17,700 (29.09%)	706 (27.73%)	112,323 (21.59%)
85+ years	6,744 (11.14%)	17,328 (10.55%)	20,852 (13.33%)	15,929 (21.07%)	13,052 (21.45%)	547 (21.48%)	74,452 (14.31%)
Sex							
Female	28,954 (47.84%)	79,442 (48.36%)	79,872 (51.07%)	39,091 (51.71%)	30,939 (50.85%)	1,279 (50.24%)	259,577 (49.90%)
Male	30,885 (51.03%)	83,226 (50.67%)	75,036 (47.97%)	35,876 (47.46%)	29,211 (48.01%)	1,220 (47.92%)	255,454 (49.11%)
Other	0	3 (0.00%)	2 (0.00%)	2 (0.00%)	0	0	7 (0.00%)
Unknown	681 (1.13%)	1,587 (0.97%)	1,500 (0.96%)	630 (0.83%)	697 (1.15%)	47 (1.85%)	5,142 (0.99%)
Race							
White	29,607 (48.92%)	105,383 (64.16%)	106,816 (68.29%)	52,957 (70.05%)	41,842 (68.77%)	1,766 (69.36%)	338,371 (65.05%)
Black or African American	10,678 (17.64%)	20,525 (12.50%)	18,745 (11.98%)	7,666 (10.14%)	6,947 (11.42%)	265 (10.41%)	64,826 (12.46%)
Asian	1,880 (3.11%)	3,709 (2.26%)	3,022 (1.93%)	2,002 (2.65%)	1,543 (2.54%)	78 (3.06%)	12,234 (2.35%)
Native Hawaiian or Other Pacific Islander	260 (0.43%)	523 (0.32%)	411 (0.26%)	175 (0.23%)	147 (0.24%)	4 (0.16%)	1,520 (0.29%)
American Indian or Alaska Native	388 (0.64%)	980 (0.60%)	943 (0.60%)	412 (0.54%)	334 (0.55%)	18 (0.71%)	3,075 (0.59%)
Other Race	6,357 (10.50%)	11,294 (6.88%)	8,243 (5.27%)	4,108 (5.43%)	3,104 (5.10%)	165 (6.48%)	33,271 (6.40%)
Unknown	11,350 (18.75%)	21,844 (13.30%)	18,230 (11.66%)	8,279 (10.95%)	6,930 (11.39%)	250 (9.82%)	66,883 (12.86%)
Ethnicity							
Hispanic or Latino	10,060 (16.62%)	18,729 (11.40%)	13,587 (8.69%)	6,221 (8.23%)	5,379 (8.84%)	238 (9.35%)	54,214 (10.42%)
Not Hispanic or Latino	38,763 (64.05%)	120,974 (73.65%)	123,597 (79.02%)	60,590 (80.15%)	49,598 (81.51%)	2,108 (82.80%)	395,630 (76.06%)
Unknown	11,697 (19.33%)	24,555 (14.95%)	19,226 (12.29%)	8,788 (11.62%)	5,870 (9.65%)	200 (7.86%)	70,336 (13.52%)
Comorbidity							
Asthma	3,859 (6.38%)	12,271 (7.47%)	13,641 (8.72%)	7,292 (9.65%)	6,623 (10.88%)	324 (12.73%)	44,010 (8.46%)
Chronic Lung Disease	2,835 (4.68%)	9,879 (6.01%)	9,790 (6.26%)	5,191 (6.87%)	4,704 (7.73%)	206 (8.09%)	32,605 (6.27%)
Chronic Obstructive Pulmonary Disease	5,049 (8.34%)	17,225 (10.49%)	21,967 (14.04%)	12,688 (16.78%)	11,456 (18.83%)	530 (20.82%)	68,915 (13.25%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019



Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 28,948,714 COVID lab results with known results of which 3,364,786 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2019

Figure 7: Weekly COVID test positivity rate by season



Influenza

Our influenza study population consists of 66,978 hospitalizations of 57,603 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	14,592 (100.00%)	379 (100.00%)	4,703 (100.00%)	17,178 (100.00%)	20,538 (100.00%)	213 (100.00%)	57,603 (100.00%)
Age Group							
< 6 months	82 (0.56%)	1 (0.26%)	23 (0.49%)	74 (0.43%)	78 (0.38%)	1 (0.47%)	259 (0.45%)
6 - <12 months	61 (0.42%)	1 (0.26%)	15 (0.32%)	59 (0.34%)	44 (0.21%)	0	180 (0.31%)
1 - <2 years	92 (0.63%)	0	29 (0.62%)	114 (0.66%)	81 (0.39%)	0	316 (0.55%)
2 - 4 years	145 (0.99%)	2 (0.53%)	50 (1.06%)	247 (1.44%)	185 (0.90%)	2 (0.94%)	631 (1.10%)
5 - 17 years	313 (2.15%)	3 (0.79%)	172 (3.66%)	555 (3.23%)	492 (2.40%)	3 (1.41%)	1,538 (2.67%)
18 - 49 years	3,115 (21.35%)	105 (27.70%)	1,059 (22.52%)	3,399 (19.79%)	4,204 (20.47%)	38 (17.84%)	11,920 (20.69%)
50 - 64 years	3,690 (25.29%)	97 (25.59%)	863 (18.35%)	3,570 (20.78%)	4,641 (22.60%)	51 (23.94%)	12,912 (22.42%)
65 - 74 years	3,080 (21.11%)	68 (17.94%)	948 (20.16%)	3,696 (21.52%)	4,443 (21.63%)	40 (18.78%)	12,275 (21.31%)
75 - 84 years	2,503 (17.15%)	73 (19.26%)	929 (19.75%)	3,480 (20.26%)	4,121 (20.07%)	47 (22.07%)	11,153 (19.36%)
85+ years	1,511 (10.35%)	29 (7.65%)	615 (13.08%)	1,984 (11.55%)	2,249 (10.95%)	31 (14.55%)	6,419 (11.14%)
Sex							
Female	7,969 (54.61%)	234 (61.74%)	2,647 (56.28%)	9,631 (56.07%)	11,238 (54.72%)	130 (61.03%)	31,849 (55.29%)
Male	6,444 (44.16%)	140 (36.94%)	2,007 (42.67%)	7,432 (43.26%)	9,132 (44.46%)	81 (38.03%)	25,236 (43.81%)
Other	0	0	0	1 (0.01%)	0	0	1 (0.00%)
Unknown	179 (1.23%)	5 (1.32%)	49 (1.04%)	114 (0.66%)	168 (0.82%)	2 (0.94%)	517 (0.90%)
Race							
White	9,502 (65.12%)	243 (64.12%)	3,182 (67.66%)	11,450 (66.66%)	13,211 (64.32%)	142 (66.67%)	37,730 (65.50%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Black or African American	2,134 (14.62%)	70 (18.47%)	660 (14.03%)	2,424 (14.11%)	3,369 (16.40%)	28 (13.15%)	8,685 (15.08%)
Asian	318 (2.18%)	4 (1.06%)	93 (1.98%)	400 (2.33%)	465 (2.26%)	3 (1.41%)	1,283 (2.23%)
Native Hawaiian or Other Pacific Islander	37 (0.25%)	0	20 (0.43%)	65 (0.38%)	81 (0.39%)	1 (0.47%)	204 (0.35%)
American Indian or Alaska Native	79 (0.54%)	2 (0.53%)	41 (0.87%)	152 (0.88%)	132 (0.64%)	3 (1.41%)	409 (0.71%)
Other Race	684 (4.69%)	13 (3.43%)	250 (5.32%)	1,096 (6.38%)	1,321 (6.43%)	17 (7.98%)	3,381 (5.87%)
Unknown	1,838 (12.60%)	47 (12.40%)	457 (9.72%)	1,591 (9.26%)	1,959 (9.54%)	19 (8.92%)	5,911 (10.26%)
Ethnicity							
Hispanic or Latino	1,255 (8.60%)	32 (8.44%)	474 (10.08%)	2,008 (11.69%)	2,455 (11.95%)	34 (15.96%)	6,258 (10.86%)
Not Hispanic or Latino	11,289 (77.36%)	298 (78.63%)	3,756 (79.86%)	13,642 (79.42%)	16,484 (80.26%)	169 (79.34%)	45,638 (79.23%)
Unknown	2,048 (14.04%)	49 (12.93%)	473 (10.06%)	1,528 (8.90%)	1,599 (7.79%)	10 (4.69%)	5,707 (9.91%)
Comorbidity							
Asthma	1,941 (13.30%)	33 (8.71%)	688 (14.63%)	2,558 (14.89%)	3,094 (15.06%)	22 (10.33%)	8,336 (14.47%)
Chronic Lung Disease	1,307 (8.96%)	22 (5.80%)	413 (8.78%)	1,488 (8.66%)	1,791 (8.72%)	18 (8.45%)	5,039 (8.75%)
Chronic Obstructive Pulmonary Disease	2,945 (20.18%)	60 (15.83%)	996 (21.18%)	3,595 (20.93%)	4,207 (20.48%)	38 (17.84%)	11,841 (20.56%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019



Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 12,281,068 influenza lab results with known results of which 928,746 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2019

Figure 11: Weekly influenza test positivity rate by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 16,751 hospitalizations of 12,213 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	2,616 (100.00%)	80 (100.00%)	2,203 (100.00%)	3,920 (100.00%)	3,352 (100.00%)	42 (100.00%)	12,213 (100.00%)
Age Group							
< 6 months	47 (1.80%)	2 (2.50%)	56 (2.54%)	137 (3.49%)	71 (2.12%)	0	313 (2.56%)
6 - <12 months	55 (2.10%)	1 (1.25%)	66 (3.00%)	97 (2.47%)	78 (2.33%)	0	297 (2.43%)
1 - <2 years	63 (2.41%)	7 (8.75%)	121 (5.49%)	139 (3.55%)	77 (2.30%)	1 (2.38%)	408 (3.34%)
2 - 4 years	68 (2.60%)	12 (15.00%)	177 (8.03%)	238 (6.07%)	128 (3.82%)	2 (4.76%)	625 (5.12%)
5 - 17 years	47 (1.80%)	0	92 (4.18%)	130 (3.32%)	86 (2.57%)	1 (2.38%)	356 (2.91%)
18 - 49 years	283 (10.82%)	13 (16.25%)	258 (11.71%)	412 (10.51%)	418 (12.47%)	4 (9.52%)	1,388 (11.36%)
50 - 64 years	545 (20.83%)	18 (22.50%)	399 (18.11%)	655 (16.71%)	598 (17.84%)	14 (33.33%)	2,229 (18.25%)
65 - 74 years	539 (20.60%)	8 (10.00%)	394 (17.88%)	763 (19.46%)	688 (20.53%)	4 (9.52%)	2,396 (19.62%)
75 - 84 years	569 (21.75%)	13 (16.25%)	407 (18.47%)	827 (21.10%)	744 (22.20%)	9 (21.43%)	2,569 (21.03%)
85+ years	400 (15.29%)	6 (7.50%)	233 (10.58%)	522 (13.32%)	464 (13.84%)	7 (16.67%)	1,632 (13.36%)
Sex							
Female	1,506 (57.57%)	39 (48.75%)	1,262 (57.29%)	2,273 (57.98%)	2,047 (61.07%)	23 (54.76%)	7,150 (58.54%)
Male	1,074 (41.06%)	39 (48.75%)	927 (42.08%)	1,625 (41.45%)	1,282 (38.25%)	19 (45.24%)	4,966 (40.66%)
Unknown	36 (1.38%)	2 (2.50%)	14 (0.64%)	22 (0.56%)	23 (0.69%)	0	97 (0.79%)
Race							
White	1,949 (74.50%)	53 (66.25%)	1,592 (72.27%)	2,797 (71.35%)	2,227 (66.44%)	29 (69.05%)	8,647 (70.80%)
Black or African American	223 (8.52%)	8 (10.00%)	236 (10.71%)	358 (9.13%)	402 (11.99%)	5 (11.90%)	1,232 (10.09%)
Asian	45 (1.72%)	0	47 (2.13%)	107 (2.73%)	66 (1.97%)	0	265 (2.17%)
Native Hawaiian or Other Pacific Islander	12 (0.46%)	0	12 (0.54%)	8 (0.20%)	5 (0.15%)	0	37 (0.30%)
American Indian or Alaska Native	17 (0.65%)	0	12 (0.54%)	36 (0.92%)	18 (0.54%)	0	83 (0.68%)
Other Race	104 (3.98%)	9 (11.25%)	111 (5.04%)	289 (7.37%)	261 (7.79%)	5 (11.90%)	779 (6.38%)
Unknown	266 (10.17%)	10 (12.50%)	193 (8.76%)	325 (8.29%)	373 (11.13%)	3 (7.14%)	1,170 (9.58%)
Ethnicity							
Hispanic or Latino	180 (6.88%)	17 (21.25%)	222 (10.08%)	542 (13.83%)	495 (14.77%)	13 (30.95%)	1,469 (12.03%)
Not Hispanic or Latino	2,100 (80.28%)	51 (63.75%)	1,761 (79.94%)	3,078 (78.52%)	2,601 (77.60%)	28 (66.67%)	9,619 (78.76%)
Unknown	336 (12.84%)	12 (15.00%)	220 (9.99%)	300 (7.65%)	256 (7.64%)	1 (2.38%)	1,125 (9.21%)
Comorbidity							

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Asthma	408 (15.60%)	9 (11.25%)	325 (14.75%)	607 (15.48%)	531 (15.84%)	8 (19.05%)	1,888 (15.46%)
Chronic Lung Disease	348 (13.30%)	9 (11.25%)	250 (11.35%)	400 (10.20%)	315 (9.40%)	3 (7.14%)	1,325 (10.85%)
Chronic Obstructive Pulmonary Disease	619 (23.66%)	13 (16.25%)	461 (20.93%)	775 (19.77%)	647 (19.30%)	9 (21.43%)	2,524 (20.67%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019

Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,639,363 HMPV lab results with known results of which 43,267 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2019

Figure 15: Weekly HMPV test positivity rate by season



Parainfluenza virus

Our parainfluenza study population consists of 16,302 hospitalizations of 13,366 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,391 (100.00%)	1,416 (100.00%)	2,349 (100.00%)	4,312 (100.00%)	3,719 (100.00%)	179 (100.00%)	13,366 (100.00%)
Age Group							
< 6 months	72 (5.18%)	81 (5.72%)	119 (5.07%)	207 (4.80%)	117 (3.15%)	3 (1.68%)	599 (4.48%)
6 - <12 months	32 (2.30%)	63 (4.45%)	89 (3.79%)	141 (3.27%)	75 (2.02%)	2 (1.12%)	402 (3.01%)
1 - <2 years	54 (3.88%)	93 (6.57%)	115 (4.90%)	168 (3.90%)	127 (3.41%)	4 (2.23%)	561 (4.20%)
2 - 4 years	73 (5.25%)	109 (7.70%)	192 (8.17%)	257 (5.96%)	149 (4.01%)	10 (5.59%)	790 (5.91%)
5 - 17 years	61 (4.39%)	83 (5.86%)	123 (5.24%)	207 (4.80%)	122 (3.28%)	11 (6.15%)	607 (4.54%)
18 - 49 years	145 (10.42%)	186 (13.14%)	293 (12.47%)	489 (11.34%)	413 (11.11%)	28 (15.64%)	1,554 (11.63%)
50 - 64 years	261 (18.76%)	256 (18.08%)	408 (17.37%)	725 (16.81%)	687 (18.47%)	25 (13.97%)	2,362 (17.67%)
65 - 74 years	243 (17.47%)	227 (16.03%)	412 (17.54%)	754 (17.49%)	730 (19.63%)	39 (21.79%)	2,405 (17.99%)
75 - 84 years	257 (18.48%)	206 (14.55%)	349 (14.86%)	808 (18.74%)	807 (21.70%)	36 (20.11%)	2,463 (18.43%)
85+ years	193 (13.87%)	112 (7.91%)	249 (10.60%)	556 (12.89%)	492 (13.23%)	21 (11.73%)	1,623 (12.14%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Sex							
Female	757 (54.42%)	730 (51.55%)	1,285 (54.70%)	2,314 (53.66%)	2,024 (54.42%)	101 (56.42%)	7,211 (53.95%)
Male	618 (44.43%)	674 (47.60%)	1,046 (44.53%)	1,959 (45.43%)	1,656 (44.53%)	76 (42.46%)	6,029 (45.11%)
Unknown	16 (1.15%)	12 (0.85%)	18 (0.77%)	39 (0.90%)	39 (1.05%)	2 (1.12%)	126 (0.94%)
Race							
White	932 (67.00%)	881 (62.22%)	1,473 (62.71%)	2,726 (63.22%)	2,338 (62.87%)	109 (60.89%)	8,459 (63.29%)
Black or African American	135 (9.71%)	190 (13.42%)	281 (11.96%)	490 (11.36%)	481 (12.93%)	34 (18.99%)	1,611 (12.05%)
Asian	54 (3.88%)	40 (2.82%)	95 (4.04%)	182 (4.22%)	99 (2.66%)	2 (1.12%)	472 (3.53%)
Native Hawaiian or Other Pacific Islander	8 (0.58%)	2 (0.14%)	8 (0.34%)	13 (0.30%)	18 (0.48%)	0	49 (0.37%)
American Indian or Alaska Native	9 (0.65%)	14 (0.99%)	21 (0.89%)	37 (0.86%)	26 (0.70%)	0	107 (0.80%)
Other Race	87 (6.25%)	143 (10.10%)	225 (9.58%)	438 (10.16%)	338 (9.09%)	15 (8.38%)	1,246 (9.32%)
Unknown	166 (11.93%)	146 (10.31%)	246 (10.47%)	426 (9.88%)	419 (11.27%)	19 (10.61%)	1,422 (10.64%)
Ethnicity							
Hispanic or Latino	101 (7.26%)	153 (10.81%)	296 (12.60%)	562 (13.03%)	547 (14.71%)	27 (15.08%)	1,686 (12.61%)
Not Hispanic or Latino	1,099 (79.01%)	1,094 (77.26%)	1,803 (76.76%)	3,331 (77.25%)	2,893 (77.79%)	139 (77.65%)	10,359 (77.50%)
Unknown	191 (13.73%)	169 (11.94%)	250 (10.64%)	419 (9.72%)	279 (7.50%)	13 (7.26%)	1,321 (9.88%)
Comorbidity							
Asthma	222 (15.96%)	211 (14.90%)	362 (15.41%)	665 (15.42%)	584 (15.70%)	32 (17.88%)	2,076 (15.53%)
Chronic Lung Disease	178 (12.80%)	131 (9.25%)	249 (10.60%)	416 (9.65%)	413 (11.11%)	17 (9.50%)	1,404 (10.50%)
Chronic Obstructive Pulmonary Disease	320 (23.01%)	289 (20.41%)	483 (20.56%)	886 (20.55%)	865 (23.26%)	39 (21.79%)	2,882 (21.56%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2019

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,720,372 parainfluenza lab results with known results of which 60,897 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2019

Figure 19: Weekly parainfluenza test positivity rate by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 36,609 hospitalizations of 29,577 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	5,874 (100.00%)	1,969 (100.00%)	4,251 (100.00%)	7,673 (100.00%)	9,621 (100.00%)	189 (100.00%)	29,577 (100.00%)
Age Group							
< 6 months	934 (15.90%)	495 (25.14%)	758 (17.83%)	1,312 (17.10%)	1,040 (10.81%)	32 (16.93%)	4,571 (15.45%)
6 - <12 months	347 (5.91%)	135 (6.86%)	265 (6.23%)	457 (5.96%)	390 (4.05%)	16 (8.47%)	1,610 (5.44%)
1 - <2 years	330 (5.62%)	177 (8.99%)	344 (8.09%)	539 (7.02%)	427 (4.44%)	7 (3.70%)	1,824 (6.17%)
2 - 4 years	335 (5.70%)	148 (7.52%)	351 (8.26%)	658 (8.58%)	394 (4.10%)	21 (11.11%)	1,907 (6.45%)
5 - 17 years	98 (1.67%)	46 (2.34%)	118 (2.78%)	241 (3.14%)	210 (2.18%)	6 (3.17%)	719 (2.43%)
18 - 49 years	335 (5.70%)	183 (9.29%)	377 (8.87%)	592 (7.72%)	847 (8.80%)	18 (9.52%)	2,352 (7.95%)
50 - 64 years	740 (12.60%)	250 (12.70%)	520 (12.23%)	885 (11.53%)	1,434 (14.90%)	18 (9.52%)	3,847 (13.01%)
65 - 74 years	891 (15.17%)	232 (11.78%)	557 (13.10%)	1,060 (13.81%)	1,605 (16.68%)	35 (18.52%)	4,380 (14.81%)
75 - 84 years	1,057 (17.99%)	188 (9.55%)	578 (13.60%)	1,127 (14.69%)	1,862 (19.35%)	26 (13.76%)	4,838 (16.36%)
85+ years	807 (13.74%)	115 (5.84%)	383 (9.01%)	802 (10.45%)	1,412 (14.68%)	10 (5.29%)	3,529 (11.93%)
Sex							
Female	3,224 (54.89%)	1,051 (53.38%)	2,191 (51.54%)	4,101 (53.45%)	5,281 (54.89%)	99 (52.38%)	15,947 (53.92%)
Male	2,610 (44.43%)	912 (46.32%)	2,033 (47.82%)	3,507 (45.71%)	4,254 (44.22%)	88 (46.56%)	13,404 (45.32%)
Unknown	40 (0.68%)	6 (0.30%)	27 (0.64%)	65 (0.85%)	86 (0.89%)	2 (1.06%)	226 (0.76%)
Race							
White	3,815 (64.95%)	1,168 (59.32%)	2,774 (65.26%)	4,989 (65.02%)	6,383 (66.34%)	100 (52.91%)	19,229 (65.01%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Black or African American	624 (10.62%)	359 (18.23%)	520 (12.23%)	863 (11.25%)	1,138 (11.83%)	36 (19.05%)	3,540 (11.97%)
Asian	172 (2.93%)	50 (2.54%)	168 (3.95%)	367 (4.78%)	305 (3.17%)	4 (2.12%)	1,066 (3.60%)
Native Hawaiian or Other Pacific Islander	11 (0.19%)	8 (0.41%)	29 (0.68%)	47 (0.61%)	33 (0.34%)	0	128 (0.43%)
American Indian or Alaska Native	46 (0.78%)	14 (0.71%)	39 (0.92%)	63 (0.82%)	77 (0.80%)	1 (0.53%)	240 (0.81%)
Other Race	501 (8.53%)	179 (9.09%)	327 (7.69%)	662 (8.63%)	640 (6.65%)	26 (13.76%)	2,335 (7.89%)
Unknown	705 (12.00%)	191 (9.70%)	394 (9.27%)	682 (8.89%)	1,045 (10.86%)	22 (11.64%)	3,039 (10.27%)
Ethnicity							
Hispanic or Latino	646 (11.00%)	270 (13.71%)	578 (13.60%)	1,179 (15.37%)	1,224 (12.72%)	39 (20.63%)	3,936 (13.31%)
Not Hispanic or Latino	4,353 (74.11%)	1,489 (75.62%)	3,289 (77.37%)	5,785 (75.39%)	7,507 (78.03%)	144 (76.19%)	22,567 (76.30%)
Unknown	875 (14.90%)	210 (10.67%)	384 (9.03%)	709 (9.24%)	890 (9.25%)	6 (3.17%)	3,074 (10.39%)
Comorbidity							
Asthma	781 (13.30%)	219 (11.12%)	539 (12.68%)	988 (12.88%)	1,349 (14.02%)	22 (11.64%)	3,898 (13.18%)
Chronic Lung Disease	490 (8.34%)	121 (6.15%)	281 (6.61%)	529 (6.89%)	760 (7.90%)	10 (5.29%)	2,191 (7.41%)
Chronic Obstructive Pulmonary Disease	1,181 (20.11%)	258 (13.10%)	686 (16.14%)	1,289 (16.80%)	1,892 (19.67%)	18 (9.52%)	5,324 (18.00%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019

Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 5,036,372 RSV lab results with known results of which 218,985 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2019

Figure 23: Weekly RSV test positivity rate by season



Rhinovirus

Our rhinovirus study population consists of 67,742 hospitalizations of 55,160 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	8,038 (100.00%)	6,449 (100.00%)	9,268 (100.00%)	15,288 (100.00%)	14,613 (100.00%)	1,504 (100.00%)	55,160 (100.00%)
Age Group							
< 6 months	409 (5.09%)	373 (5.78%)	692 (7.47%)	857 (5.61%)	682 (4.67%)	50 (3.32%)	3,063 (5.55%)
6 - <12 months	215 (2.67%)	235 (3.64%)	378 (4.08%)	444 (2.90%)	370 (2.53%)	26 (1.73%)	1,668 (3.02%)
1 - <2 years	333 (4.14%)	472 (7.32%)	780 (8.42%)	844 (5.52%)	683 (4.67%)	59 (3.92%)	3,171 (5.75%)
2 - 4 years	477 (5.93%)	570 (8.84%)	1,194 (12.88%)	1,404 (9.18%)	1,000 (6.84%)	94 (6.25%)	4,739 (8.59%)
5 - 17 years	481 (5.98%)	713 (11.06%)	1,167 (12.59%)	1,754 (11.47%)	1,443 (9.87%)	131 (8.71%)	5,689 (10.31%)
18 - 49 years	1,321 (16.43%)	1,332 (20.65%)	1,342 (14.48%)	2,474 (16.18%)	2,632 (18.01%)	337 (22.41%)	9,438 (17.11%)
50 - 64 years	1,523 (18.95%)	961 (14.90%)	1,149 (12.40%)	2,205 (14.42%)	2,261 (15.47%)	279 (18.55%)	8,378 (15.19%)
65 - 74 years	1,294 (16.10%)	793 (12.30%)	1,126 (12.15%)	2,150 (14.06%)	2,255 (15.43%)	235 (15.62%)	7,853 (14.24%)
75 - 84 years	1,156 (14.38%)	609 (9.44%)	884 (9.54%)	1,908 (12.48%)	1,957 (13.39%)	200 (13.30%)	6,714 (12.17%)
85+ years	829 (10.31%)	391 (6.06%)	556 (6.00%)	1,248 (8.16%)	1,330 (9.10%)	93 (6.18%)	4,447 (8.06%)
Sex							
Female	3,953 (49.18%)	3,199 (49.60%)	4,406 (47.54%)	7,572 (49.53%)	7,335 (50.20%)	736 (48.94%)	27,201 (49.31%)
Male	3,979 (49.50%)	3,193 (49.51%)	4,783 (51.61%)	7,600 (49.71%)	7,140 (48.86%)	753 (50.07%)	27,448 (49.76%)
Unknown	106 (1.32%)	57 (0.88%)	79 (0.85%)	116 (0.76%)	138 (0.94%)	15 (1.00%)	511 (0.93%)
Race							
White	5,088 (63.30%)	3,771 (58.47%)	5,372 (57.96%)	8,853 (57.91%)	8,512 (58.25%)	906 (60.24%)	32,502 (58.92%)
Black or African American	1,016 (12.64%)	1,020 (15.82%)	1,367 (14.75%)	2,206 (14.43%)	2,212 (15.14%)	259 (17.22%)	8,080 (14.65%)
Asian	247 (3.07%)	231 (3.58%)	425 (4.59%)	661 (4.32%)	412 (2.82%)	30 (1.99%)	2,006 (3.64%)
Native Hawaiian or Other Pacific Islander	29 (0.36%)	26 (0.40%)	41 (0.44%)	60 (0.39%)	56 (0.38%)	2 (0.13%)	214 (0.39%)
American Indian or Alaska Native	61 (0.76%)	41 (0.64%)	65 (0.70%)	123 (0.80%)	79 (0.54%)	9 (0.60%)	378 (0.69%)
Other Race	646 (8.04%)	793 (12.30%)	1,140 (12.30%)	1,787 (11.69%)	1,636 (11.20%)	153 (10.17%)	6,155 (11.16%)
Unknown	951 (11.83%)	567 (8.79%)	858 (9.26%)	1,598 (10.45%)	1,706 (11.67%)	145 (9.64%)	5,825 (10.56%)
Ethnicity							

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Hispanic or Latino	725 (9.02%)	812 (12.59%)	1,342 (14.48%)	2,414 (15.79%)	2,464 (16.86%)	258 (17.15%)	8,015 (14.53%)
Not Hispanic or Latino	6,188 (76.98%)	4,987 (77.33%)	7,083 (76.42%)	11,373 (74.39%)	10,932 (74.81%)	1,172 (77.93%)	41,735 (75.66%)
Unknown	1,125 (14.00%)	650 (10.08%)	843 (9.10%)	1,501 (9.82%)	1,217 (8.33%)	74 (4.92%)	5,410 (9.81%)
Comorbidity							
Asthma	1,424 (17.72%)	1,106 (17.15%)	1,482 (15.99%)	2,522 (16.50%)	2,475 (16.94%)	292 (19.41%)	9,301 (16.86%)
Chronic Lung Disease	940 (11.69%)	512 (7.94%)	637 (6.87%)	1,098 (7.18%)	1,058 (7.24%)	158 (10.51%)	4,403 (7.98%)
Chronic Obstructive Pulmonary Disease	1,729 (21.51%)	981 (15.21%)	1,228 (13.25%)	2,198 (14.38%)	2,238 (15.32%)	313 (20.81%)	8,687 (15.75%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,569,116 rhinovirus lab results with known results of which 243,681 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2019

Figure 27: Weekly rhinovirus test positivity rate by season



Infants and children (age 0-4)

Our infants and children study population consists of 42,395 hospitalizations of 32,744 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	4,526 (100.00%)	3,543 (100.00%)	7,457 (100.00%)	9,455 (100.00%)	7,311 (100.00%)	452 (100.00%)	32,744 (100.00%)
Age Group							
< 6 months	1,652 (36.50%)	1,262 (35.62%)	2,389 (32.04%)	2,998 (31.71%)	2,336 (31.95%)	110 (24.34%)	10,747 (32.82%)
6 - <12 months	747 (16.50%)	487 (13.75%)	1,067 (14.31%)	1,400 (14.81%)	1,171 (16.02%)	58 (12.83%)	4,930 (15.06%)
1 - <2 years	927 (20.48%)	847 (23.91%)	1,646 (22.07%)	1,993 (21.08%)	1,645 (22.50%)	111 (24.56%)	7,169 (21.89%)
2 - 4 years	1,200 (26.51%)	947 (26.73%)	2,355 (31.58%)	3,064 (32.41%)	2,159 (29.53%)	173 (38.27%)	9,898 (30.23%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Sex							
Female	1,999 (44.17%)	1,492 (42.11%)	3,110 (41.71%)	4,100 (43.36%)	3,173 (43.40%)	178 (39.38%)	14,052 (42.91%)
Male	2,526 (55.81%)	2,050 (57.86%)	4,334 (58.12%)	5,346 (56.54%)	4,124 (56.41%)	274 (60.62%)	18,654 (56.97%)
Unknown	1 (0.02%)	1 (0.03%)	13 (0.17%)	9 (0.10%)	14 (0.19%)	0	38 (0.12%)
Race							
White	2,166 (47.86%)	1,684 (47.53%)	3,688 (49.46%)	4,539 (48.01%)	3,409 (46.63%)	179 (39.60%)	15,665 (47.84%)
Black or African American	801 (17.70%)	702 (19.81%)	1,283 (17.21%)	1,509 (15.96%)	1,188 (16.25%)	82 (18.14%)	5,565 (17.00%)
Asian	261 (5.77%)	161 (4.54%)	436 (5.85%)	697 (7.37%)	389 (5.32%)	20 (4.42%)	1,964 (6.00%)
Native Hawaiian or Other Pacific Islander	29 (0.64%)	25 (0.71%)	58 (0.78%)	60 (0.63%)	50 (0.68%)	0	222 (0.68%)
American Indian or Alaska Native	52 (1.15%)	32 (0.90%)	71 (0.95%)	115 (1.22%)	59 (0.81%)	1 (0.22%)	330 (1.01%)
Other Race	782 (17.28%)	668 (18.85%)	1,228 (16.47%)	1,588 (16.80%)	1,206 (16.50%)	110 (24.34%)	5,582 (17.05%)
Unknown	435 (9.61%)	271 (7.65%)	693 (9.29%)	947 (10.02%)	1,010 (13.81%)	60 (13.27%)	3,416 (10.43%)
Ethnicity							
Hispanic or Latino	1,022 (22.58%)	726 (20.49%)	1,597 (21.42%)	2,405 (25.44%)	1,902 (26.02%)	127 (28.10%)	7,779 (23.76%)
Not Hispanic or Latino	2,979 (65.82%)	2,543 (71.78%)	5,329 (71.46%)	6,311 (66.75%)	4,821 (65.94%)	293 (64.82%)	22,276 (68.03%)
Unknown	525 (11.60%)	274 (7.73%)	531 (7.12%)	739 (7.82%)	588 (8.04%)	32 (7.08%)	2,689 (8.21%)
Virus							
COVID	302 (6.67%)	566 (15.98%)	1,643 (22.03%)	1,062 (11.23%)	1,115 (15.25%)	122 (26.99%)	4,810 (14.69%)
HMPV	233 (5.15%)	22 (0.62%)	420 (5.63%)	611 (6.46%)	354 (4.84%)	3 (0.66%)	1,643 (5.02%)
RSV	1,946 (43.00%)	955 (26.95%)	1,718 (23.04%)	2,966 (31.37%)	2,251 (30.79%)	76 (16.81%)	9,912 (30.27%)
influenza	380 (8.40%)	4 (0.11%)	117 (1.57%)	494 (5.22%)	388 (5.31%)	3 (0.66%)	1,386 (4.23%)
parainfluenza	231 (5.10%)	346 (9.77%)	515 (6.91%)	773 (8.18%)	468 (6.40%)	19 (4.20%)	2,352 (7.18%)
rhinovirus	1,434 (31.68%)	1,650 (46.57%)	3,044 (40.82%)	3,549 (37.54%)	2,735 (37.41%)	229 (50.66%)	12,641 (38.61%)
Comorbidity							
Asthma	344 (7.60%)	243 (6.86%)	451 (6.05%)	626 (6.62%)	508 (6.95%)	47 (10.40%)	2,219 (6.78%)
Chronic Lung Disease	46 (1.02%)	21 (0.59%)	35 (0.47%)	62 (0.66%)	56 (0.77%)	4 (0.88%)	224 (0.68%)
Chronic Obstructive Pulmonary Disease	10 (0.22%)	3 (0.08%)	11 (0.15%)	12 (0.13%)	15 (0.21%)	0	51 (0.16%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Test positivity rate over time

We included 4,784,473 lab results with known results of infants and children under age five. Of those tests, 540,938 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2019 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 398,433 hospitalizations of 371,052 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	45,262 (100.00%)	85,707 (100.00%)	94,309 (100.00%)	74,325 (100.00%)	68,868 (100.00%)	2,581 (100.00%)	371,052 (100.00%)
Age Group							
65 - 74 years	18,320 (40.48%)	36,512 (42.60%)	36,150 (38.33%)	24,382 (32.80%)	22,678 (32.93%)	848 (32.86%)	138,890 (37.43%)
75 - 84 years	16,458 (36.36%)	31,214 (36.42%)	35,271 (37.40%)	28,902 (38.89%)	27,191 (39.48%)	1,024 (39.67%)	140,060 (37.75%)
85+ years	10,484 (23.16%)	17,981 (20.98%)	22,888 (24.27%)	21,041 (28.31%)	18,999 (27.59%)	709 (27.47%)	92,102 (24.82%)
Sex							
Female	23,030 (50.88%)	41,793 (48.76%)	47,332 (50.19%)	39,204 (52.75%)	36,152 (52.49%)	1,323 (51.26%)	188,834 (50.89%)
Male	22,028 (48.67%)	43,623 (50.90%)	46,628 (49.44%)	34,786 (46.80%)	32,261 (46.84%)	1,208 (46.80%)	180,534 (48.65%)
Unknown	204 (0.45%)	291 (0.34%)	349 (0.37%)	335 (0.45%)	455 (0.66%)	50 (1.94%)	1,684 (0.45%)
Race							
White	28,662 (63.32%)	61,887 (72.21%)	71,236 (75.53%)	56,085 (75.46%)	50,550 (73.40%)	1,955 (75.75%)	270,375 (72.87%)
Black or African American	5,319 (11.75%)	7,292 (8.51%)	7,582 (8.04%)	5,554 (7.47%)	6,100 (8.86%)	209 (8.10%)	32,056 (8.64%)
Asian	978 (2.16%)	1,505 (1.76%)	1,569 (1.66%)	1,729 (2.33%)	1,552 (2.25%)	58 (2.25%)	7,391 (1.99%)
Native Hawaiian or Other Pacific Islander	48 (0.11%)	125 (0.15%)	121 (0.13%)	126 (0.17%)	113 (0.16%)	4 (0.15%)	537 (0.14%)
American Indian or Alaska Native	130 (0.29%)	252 (0.29%)	327 (0.35%)	326 (0.44%)	281 (0.41%)	11 (0.43%)	1,327 (0.36%)
Other Race	2,047 (4.52%)	3,139 (3.66%)	2,845 (3.02%)	2,928 (3.94%)	2,867 (4.16%)	96 (3.72%)	13,922 (3.75%)
Unknown	8,078 (17.85%)	11,507 (13.43%)	10,629 (11.27%)	7,577 (10.19%)	7,405 (10.75%)	248 (9.61%)	45,444 (12.25%)
Ethnicity							
Hispanic or Latino	2,687 (5.94%)	4,560 (5.32%)	4,100 (4.35%)	4,193 (5.64%)	4,690 (6.81%)	196 (7.59%)	20,426 (5.50%)
Not Hispanic or Latino	33,134 (73.20%)	66,657 (77.77%)	77,347 (82.01%)	61,225 (82.37%)	57,374 (83.31%)	2,196 (85.08%)	297,933 (80.29%)
Unknown	9,441 (20.86%)	14,490 (16.91%)	12,862 (13.64%)	8,907 (11.98%)	6,804 (9.88%)	189 (7.32%)	52,693 (14.20%)
Virus							

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
COVID	29,933 (66.13%)	82,637 (96.42%)	85,689 (90.86%)	52,640 (70.82%)	43,709 (63.47%)	1,748 (67.73%)	296,356 (79.87%)
HMPV	1,508 (3.33%)	27 (0.03%)	1,034 (1.10%)	2,112 (2.84%)	1,896 (2.75%)	20 (0.77%)	6,597 (1.78%)
RSV	2,755 (6.09%)	535 (0.62%)	1,518 (1.61%)	2,989 (4.02%)	4,879 (7.08%)	71 (2.75%)	12,747 (3.44%)
influenza	7,094 (15.67%)	170 (0.20%)	2,492 (2.64%)	9,160 (12.32%)	10,813 (15.70%)	118 (4.57%)	29,847 (8.04%)
parainfluenza	693 (1.53%)	545 (0.64%)	1,010 (1.07%)	2,118 (2.85%)	2,029 (2.95%)	96 (3.72%)	6,491 (1.75%)
rhinovirus	3,279 (7.24%)	1,793 (2.09%)	2,566 (2.72%)	5,306 (7.14%)	5,542 (8.05%)	528 (20.46%)	19,014 (5.12%)
Comorbidity							
Asthma	3,787 (8.37%)	6,210 (7.25%)	7,895 (8.37%)	7,501 (10.09%)	7,532 (10.94%)	305 (11.82%)	33,230 (8.96%)
Chronic Lung Disease	3,394 (7.50%)	6,024 (7.03%)	7,063 (7.49%)	6,274 (8.44%)	6,171 (8.96%)	280 (10.85%)	29,206 (7.87%)
Chronic Obstructive Pulmonary Disease	8,382 (18.52%)	14,016 (16.35%)	19,093 (20.25%)	16,551 (22.27%)	16,457 (23.90%)	724 (28.05%)	75,223 (20.27%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Test positivity rate over time

We included 15,541,680 lab results with known results of adults aged 65 and over. Of those tests, 1,111,556 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2019 for adults 65 years or older



Discussion and conclusion

In the final week of October, respiratory virus-associated hospitalizations accounted for 1.9% of all hospitalizations, down from 2.3% in late September. The rate of hospitalizations associated with respiratory viruses decreased by 18.7% from September 30, 2024, to October 28, 2024. The decline in COVID-associated hospitalizations (-39.3%) was the most substantial decrease. RSV-, Influenza- and HMPV-associated hospitalizations increased significantly (+191.5%, +100.0% and +123.4%, respectively); however, the percentage of overall hospitalizations associated with either HMPV or influenza remained low. Parainfluenza hospitalizations showed a moderate increase (+16.1%), while rhinovirus-associated hospitalizations decreased slightly (-14.4%).

In the population aged 0–4 years, respiratory virus-associated hospitalizations increased by 21.6% from September 30, 2024, to October 28, 2024. COVID-associated

hospitalizations declined by 18.%, while RSV-associated hospitalizations surged dramatically by +233.3%. RSV-associated hospitalizations now account for 2.4% of all hospitalizations within this population. Parainfluenza-associated hospitalizations decreased slightly by 24.3%. In late October, 5.1% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus remaining a significant contributor at 3.2%.

Among older adults (age 65 and over), hospitalizations associated with respiratory viruses decreased by 26.8% from September 30, 2024, to October 28, 2024. COVID-associated hospitalizations declined significantly (-40.9%), while influenza-associated hospitalizations increased by 91.5%. Hospitalizations related to RSV rose substantially (+137.0%), while rhinovirus-associated hospitalizations decreased slightly (-17.6%). By late October, respiratory virus-associated hospitalizations accounted for 2.0% of all hospitalizations in this age group, with COVID and rhinovirus contributing 1.2% and 0.5%, respectively.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed November 19, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). The unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High

Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy